2,2-dipropyl-pyrrolidine | 92144-56-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 2,2-dipropyl-pyrrolidine
• 英文别名: 2,2-Dipropyl-pyrrolidin；2,2-Dipropylpyrrolidine
• CAS: 92144-56-4
• 化学式: C₁₀H₂₁N
• 分子量: 155.283
• InChiKey: RCDUVHIXLKAHCE-UHFFFAOYSA-N

物化性质

• 沸点：
  190.9±8.0 °C(Predicted)
• 密度：
  0.811±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-甲氧基-1-吡咯烷 、 propyllithium 以 乙醚 为溶剂， 反应 12.0h， 以67%的产率得到2,2-dipropyl-pyrrolidine
  参考文献：
  名称：

  Reaction of organolithium reagents with lactim ethers: preparation of cyclic 2-alkyl imines or 2,2-dialkyl amines

  摘要：

  DOI：

  10.1021/jo00197a013

文献信息

• Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof
  申请人：Hardy Larry Wendell

  公开号：US20110319380A1

  公开（公告）日：2011-12-29

  Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

  本文提供了化合物及其合成方法。本文中提供的化合物可用于治疗、预防和/或管理各种疾病，如神经系统疾病、神经退行性疾病、神经精神疾病、认知、学习或记忆障碍、胃肠道疾病、下尿路障碍和癌症。本文提供的化合物在中枢神经系统或外周调节代谢性谷氨酸受体5(mGluR5)的活性。本文还提供了含有这些化合物的药物制剂及其使用方法。
• NOVEL PYRAZOLE COMPOUNDS
  申请人：Eli Lilly and Company

  公开号：US20140162967A1

  公开（公告）日：2014-06-12

  The present invention provides a compound of Formula II: wherein X represents the following: or a pharmaceutically acceptable salt thereof.

  本发明提供了一个II式化合物，其中X代表以下内容：或其药学上可接受的盐。
• COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF
  申请人：Sunovion Pharmaceuticals Inc.

  公开号：US20140349992A1

  公开（公告）日：2014-11-27

  Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

  本文提供了化合物及其合成方法。这些化合物可用于治疗、预防和/或管理各种疾病，如神经疾病、神经退行性疾病、神经精神疾病、认知、学习或记忆障碍、胃肠道疾病、下尿路障碍和癌症等。本文提供的化合物在中枢神经系统或外周调节代谢性谷氨酸受体5 (mGluR5) 的活性。本文还提供了含有这些化合物的药物制剂及其使用方法。
• Lukes et al., Collection of Czechoslovak Chemical Communications, 1947, vol. 12, p. 647,650
  作者：Lukes et al.

  DOI：——

  日期：——
• ZEZZA, CH. A.;SMITH, M. B.;ROSS, B. A.;ARHIN, AKWASI;CRONIN, P. L. E., J. ORG. CHEM., 1984, 49, N 23, 4397-4399
  作者：ZEZZA, CH. A.、SMITH, M. B.、ROSS, B. A.、ARHIN, AKWASI、CRONIN, P. L. E.

  DOI：——

  日期：——